RefleXion Showcases Expanding Clinical Evidence for SCINTIX Therapy in 15 Scientific Presentations at ASTRO 2025, Including First Reported Outcomes

A first-in-human pilot study demonstrates potential feasibility of PSMA-directed SCINTIX therapy in patients with prostate cancer^[1]

HAYWARD, Calif., Sept. 26, 2025 — RefleXion Medical, an external‑beam theranostic oncology company, today announced that researchers and early adopters from leading academic centers will deliver 15 scientific presentations featuring SCINTIX® biology‑guided radiotherapy (BgRT) and the RefleXion^® X1 platform at the 2025 American Society for Radiation Oncology Annual Meeting, Sept. 27–31 in San Francisco. In parallel, Advances in Oncology published results from a pilot study^[2] at City of Hope demonstrating the feasibility of using prostate specific membrane antigen (PSMA) to direct SCINTIX therapy in patients with prostate cancer.

We are encouraged by the continued excitement for SCINTIX therapy and the RefleXion platform from our clinical collaborators

Sean Shirvani, MD, MPH
Chief Medical Officer at RefleXion

“We are encouraged by the continued excitement for SCINTIX therapy and the RefleXion platform from our clinical collaborators,” said Sean Shirvani, MD, MPH, chief medical officer at RefleXion. “These new data –  multi-tumor treatments, the first outcomes from the prospective PREMIER registry, and a pioneering PSMA pilot study – demonstrate meaningful progress toward integrating biology as a central driver of the radiotherapy workflow and advancing the role of BgRT in cancer care.”

The pilot study evaluated whether the X1 platform could detect PSMA positron emission tomography (PET) signals from the diagnostic radiopharmaceutical PYLARIFY^® (piflufolastat F18) to guide SCINTIX therapy in prostate cancer. In 18 of 20 patients, PET-avid tumors were visualized, laying the foundation for further evaluation of this imaging agent as a SCINTIX bioguide thereby creating an entirely new application for it.

“Biology-guided radiotherapy using targeted PET radiopharmaceuticals to guide radiotherapy represents a promising new dimension in radiation oncology and warrants further investigation,” noted lead author Bo Liu, PhD, and colleagues.^[3]

The following presentations highlight research showcasing the potential of SCINTIX therapy and the X1 platform at ASTRO 2025. Detailed information on all 15 presentations may be found here.

Featured Scientific Presentations at ASTRO 2025:

Oral: First-in-Human Dual Modality Radiotherapy Treatment in a Single Plan Using BGRT: A Case Report (Henry Park, MD, MPH)
Monday, Sept. 29 at 5:10 PM in Room 154

Oral: Clinical Outcomes of BGRT for Osseous Metastases (Pule Wang, PhD)
Monday, Sept. 29 at 5:20 PM in Room 154

Oral: A Prospective Pilot Study of 18F-FDG Imaging with the PET-CT Subsystem on a BGRT Machine (Chunhui Han, PhD)
Wednesday, Oct. 1 at 12:20 PM

Poster: Feasibility of Combining Same-Day Biology-guided Radiotherapy (BGRT) and Stereotactic Body Radiotherapy for Patients with Oligometastatic Disease on a PET-LINAC Platform, Bin Cai, PhD
Sunday, Sept. 28, 2:30-4:30 PM in Hall F

Poster: Biology-guided Radiotherapy for Lung and Bone Tumors: Early Insights Into Local Control Outcomes From the Prospective PREMIER Registry, Tu Dan, MD
Sunday, Sept. 28, 4:45-6:00PM in Hall F

RefleXion (booth #1433) will also present early results characterizing performance of its future, next-generation platform^[4] that offers a 20-fold increase in PET sensitivity, which may increase patient eligibility for SCINTIX therapy. Presentations will be held every 30 minutes in the RefleXion booth during exhibit hours.

About RefleXion Medical

RefleXion is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology‑guided radiotherapy, a novel therapy that uses a single radiotracer injection to turn cancer cells into real‑time biological beacons to guide external‑beam radiotherapy. SCINTIX therapy is FDA‑cleared for FDG‑guided treatment of lung and bone tumors, including metastases, and is under investigation for additional tracers and indications. The RefleXion X1 platform is also cleared for conventional image‑guided radiotherapy for solid tumors anywhere in the body. For more information, visit www.reflexion.com.

Media Contact
contact@reflexion.com
+1-650-239-9070

[1] Investigational use only. SCINTIX therapy is not FDA-cleared for use with PYLARIFY (piflufolastat F18) in treating prostate cancer patients.
[2]  Liu, Bo et al. A Prospective First-In-Human Pilot Study [18F]-DCFPyL PSMA Imaging on the RefleXion X1 PET-CT Subsystem in Patients with Prostate Cancer. Advances in Radiation Oncology. Volume 0, Issue 0, 101902.
[3] Morton, Will. (2025, Sept. 19). Radiation oncologists put RefleXion’s X1 system to the test. AuntMinnie.com, https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15755886/radiation-oncologists-put-reflexions-x1-system-to-the-test
[4] The future, next-generation, platform is in development. It has not been approved by FDA, and its safety and effectiveness has not been established. It is not available for sale.